Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(28.6%)

N/A

2(28.6%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(2)

N/A(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02464007Phase 1Terminated

Study of rSIFN-co for Patients With Advanced Solid Tumors

Role: collaborator

NCT02546102Phase 3Suspended

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Role: collaborator

NCT02872701Phase 2Completed

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Role: collaborator

NCT04703738Not ApplicableUnknown

Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

Role: collaborator

NCT04260152Not ApplicableCompleted

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

Role: collaborator

NCT03053635Phase 1Completed

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Role: collaborator

NCT03037970Phase 2Unknown

Evaluation of ABSOLVE in Diabetic Foot Ulcers

Role: collaborator

All 7 trials loaded